Noida, UP -- (SBWire) -- 04/09/2015 --According to a new research report by RNCOS entitled, "US Generic Drug Market Outlook 2018", The large number of drugs going off-patent in the US presents opportunities for domestic as well as foreign generic drug makers to introduce Generic equivalents of branded products. Some of the players competing in the market include Sun Pharmaceutical Industries Ltd, Teva, Mylan, Actavis, Lupin, Dr Reddy's Laboratories Ltd, Cipla Ltd, Novartis, Roche and Daiichi Sankyo. Patent expirations are estimated to affect more than US$ 30 Billion sales of branded drugs in 2014. A generic drug generally takes about 80% of the branded drug market share and prices at about 20% of the branded counterpart. Anticipating the opportunity, drug makers around the globe are building a strong pipeline of products to be sold in the US and have been filing abbreviated new drug applications (ANDA) to the US Food and Drug Administration (FDA), seeking approval for generic drugs. Some of the major drugs whose patents are on the verge of expiry include Teva Pharmaceutical industries Ltd's multiple sclerosis brand Capaxone, AstraZeneca SA's hyperacidity drug Nexium, and Boehringer Ingelheim's cardiac drug Micardis.
The report is spread in over 100 pages and provides an in-depth research and rational analysis of the current status and future prospect of the US Generics industry. The report provides a clear picture of Generics market, its growth, and drivers & challenges pertaining to it. In addition to this, the study further highlights emerging trends and developments which have been occurring in the US over the years, market potential of Generics in key therapeutic segments, competitive landscape and regulatory scenario, among other pointers. It also provides valuable information to pharmaceutical and generic drug companies and investors looking to enter this market. Facts and figures regarding market size, growth, share, regulatory environment and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM731.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.
Ongoing Patent Cliff to Drive the US Generics Market!
“Running number of patent expirations estimated to affect more than US$30 Billion sales of branded drugs in 2014”, says RNCOS.